CRISPR/Cas9 as a therapeutic tool for triple negative breast cancer: from bench to clinics

Frontiers in Molecular Biosciences

Molecular Biosciences

Prashant Kumar Tiwari¹  Sanjay Kumar¹  Mandeep Chouhan¹  Deen Dayal²  Lung-Wen Tsai³  Tin-Hsien Ko⁴  Chih-Wei Chiang⁵  Himanshu Narayan Singh⁶  Rajni Dubey⁷  Kundan Kumar Chaubey⁸ 

[1] Biological and Bio-Computational Lab, Department of Life Sciences, Sharda School of Basic Science and Research, Sharda University, Greater Noida, Uttar Pradesh, India;Department of Biotechnology, GLA University, Mathura, Uttar Pradesh, India;Department of Medicine Research, Taipei Medical University Hospital, Taipei City, Taiwan;Department of Information Technology Office, Taipei Medical University Hospital, Taipei City, Taiwan;Graduate Institute of Data Science, College of Management, Taipei Medical University, Taipei City, Taiwan;Department of Orthopedics, Taipei Medical University Hospital, Taipei City, Taiwan;Department of Orthopedics, Taipei Medical University Hospital, Taipei City, Taiwan;Department of Orthopedic Surgery, School of Medicine, College of Medicine, Taipei Medical University, Taipei City, Taiwan;Department of Systems Biology, Columbia University Irving Medical Centre, New York, NY, United States;Division of Cardiology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei City, Taiwan;Division of Research and Innovation, School of Applied and Life Sciences, Uttaranchal University, Dehradun, Uttarakhand, India;

关键词: triple negative breast cancer;    CRISPR/Cas9;    gene editing;    immunotherapy;    drug resistance and artificial intelligence;   

DOI  :  10.3389/fmolb.2023.1214489

 received in 2023-04-29, accepted in 2023-06-20,  发布年份 2023

来源: Frontiers

【 摘 要 】

Clustered regularly interspaced short palindromic repeats (CRISPR) is a third-generation genome editing method that has revolutionized the world with its high throughput results. It has been used in the treatment of various biological diseases and infections. Various bacteria and other prokaryotes such as archaea also have CRISPR/Cas9 systems to guard themselves against bacteriophage. Reportedly, CRISPR/Cas9-based strategy may inhibit the growth and development of triple-negative breast cancer (TNBC) via targeting the potentially altered resistance genes, transcription, and epigenetic regulation. These therapeutic activities could help with the complex issues such as drug resistance which is observed even in TNBC. Currently, various methods have been utilized for the delivery of CRISPR/Cas9 into the targeted cell such as physical (microinjection, electroporation, and hydrodynamic mode), viral (adeno-associated virus and lentivirus), and non-viral (liposomes and lipid nano-particles). Although different models have been developed to investigate the molecular causes of TNBC, but the lack of sensitive and targeted delivery methods for in-vivo genome editing tools limits their clinical application. Therefore, based on the available evidences, this review comprehensively highlighted the advancement, challenges limitations, and prospects of CRISPR/Cas9 for the treatment of TNBC. We also underscored how integrating artificial intelligence and machine learning could improve CRISPR/Cas9 strategies in TNBC therapy.

【 授权许可】

Unknown   
Copyright © 2023 Tiwari, Ko, Dubey, Chouhan, Tsai, Singh, Chaubey, Dayal, Chiang and Kumar.